These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 17206941)

  • 1. Review article: tolevamer, a novel toxin-binding polymer: overview of preclinical pharmacology and physicochemical properties.
    Barker RH; Dagher R; Davidson DM; Marquis JK
    Aliment Pharmacol Ther; 2006 Dec; 24(11-12):1525-34. PubMed ID: 17206941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea.
    Louie TJ; Peppe J; Watt CK; Johnson D; Mohammed R; Dow G; Weiss K; Simon S; John JF; Garber G; Chasan-Taber S; Davidson DM;
    Clin Infect Dis; 2006 Aug; 43(4):411-20. PubMed ID: 16838228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.
    Johnson S; Louie TJ; Gerding DN; Cornely OA; Chasan-Taber S; Fitts D; Gelone SP; Broom C; Davidson DM;
    Clin Infect Dis; 2014 Aug; 59(3):345-54. PubMed ID: 24799326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxin binding of tolevamer, a polyanionic drug that protects against antibiotic-associated diarrhea.
    Braunlin W; Xu Q; Hook P; Fitzpatrick R; Klinger JD; Burrier R; Kurtz CB
    Biophys J; 2004 Jul; 87(1):534-9. PubMed ID: 15240486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolevamer, an orally administered, toxin-binding polymer for Clostridium difficile-associated diarrhea.
    Scheinfeld N; Biggers K
    Curr Opin Investig Drugs; 2008 Aug; 9(8):913-24. PubMed ID: 18666039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis.
    Kurtz CB; Cannon EP; Brezzani A; Pitruzzello M; Dinardo C; Rinard E; Acheson DW; Fitzpatrick R; Kelly P; Shackett K; Papoulis AT; Goddard PJ; Barker RH; Palace GP; Klinger JD
    Antimicrob Agents Chemother; 2001 Aug; 45(8):2340-7. PubMed ID: 11451694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolevamer, an anionic polymer, neutralizes toxins produced by the BI/027 strains of Clostridium difficile.
    Hinkson PL; Dinardo C; DeCiero D; Klinger JD; Barker RH
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2190-5. PubMed ID: 18391047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer.
    Weiss K
    Int J Antimicrob Agents; 2009 Jan; 33(1):4-7. PubMed ID: 18804351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection.
    Baines SD; Freeman J; Wilcox MH
    Antimicrob Agents Chemother; 2009 May; 53(5):2202-4. PubMed ID: 19223641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clostridium difficile: new therapeutic options.
    Balagopal A; Sears CL
    Curr Opin Pharmacol; 2007 Oct; 7(5):455-8. PubMed ID: 17644040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models.
    Tian JH; Fuhrmann SR; Kluepfel-Stahl S; Carman RJ; Ellingsworth L; Flyer DC
    Vaccine; 2012 Jun; 30(28):4249-58. PubMed ID: 22537987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative therapies for Clostridium difficile infections.
    Venuto C; Butler M; Ashley ED; Brown J
    Pharmacotherapy; 2010 Dec; 30(12):1266-78. PubMed ID: 21114394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Combination of Three Fully Human Toxin A- and Toxin B-Specific Monoclonal Antibodies Protects against Challenge with Highly Virulent Epidemic Strains of Clostridium difficile in the Hamster Model.
    Anosova NG; Cole LE; Li L; Zhang J; Brown AM; Mundle S; Zhang J; Ray S; Ma F; Garrone P; Bertraminelli N; Kleanthous H; Anderson SF
    Clin Vaccine Immunol; 2015 Jul; 22(7):711-25. PubMed ID: 25924765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new formulation of tolevamer, a novel nonantibiotic polymer, is safe and well-tolerated in healthy volunteers: a randomized phase I trial.
    Peppe J; Porzio A; Davidson DM
    Br J Clin Pharmacol; 2008 Jul; 66(1):102-9. PubMed ID: 18341677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model.
    Ochsner UA; Bell SJ; O'Leary AL; Hoang T; Stone KC; Young CL; Critchley IA; Janjic N
    J Antimicrob Chemother; 2009 May; 63(5):964-71. PubMed ID: 19251726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters.
    Babcock GJ; Broering TJ; Hernandez HJ; Mandell RB; Donahue K; Boatright N; Stack AM; Lowy I; Graziano R; Molrine D; Ambrosino DM; Thomas WD
    Infect Immun; 2006 Nov; 74(11):6339-47. PubMed ID: 16966409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic role of stool culture & toxin detection in antibiotic associated diarrhoea due to Clostridium difficile in children.
    Gogate A; De A; Nanivadekar R; Mathur M; Saraswathi K; Jog A; Kulkarni MV
    Indian J Med Res; 2005 Dec; 122(6):518-24. PubMed ID: 16518003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oritavancin does not induce Clostridium difficile germination and toxin production in hamsters or a human gut model.
    Freeman J; Marquis M; Crowther GS; Todhunter SL; Fawley WN; Chilton CH; Moeck G; Lehoux D; Wilcox MH
    J Antimicrob Chemother; 2012 Dec; 67(12):2919-26. PubMed ID: 22899803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of A/B toxin and isolation of Clostridium difficile and Clostridium perfringens from foals.
    Silva RO; Ribeiro MG; Palhares MS; Borges AS; Maranhão RP; Silva MX; Lucas TM; Olivo G; Lobato FC
    Equine Vet J; 2013 Nov; 45(6):671-5. PubMed ID: 23452044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-infection of hamsters with toxin A or toxin B-deficient Clostridium difficile strains.
    Szczesny A; Martirosian G; Cohen S; Silva J
    Pol J Microbiol; 2005; 54(4):301-4. PubMed ID: 16599301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.